Aim: Among HIV-infected adults receiving efavirenz fixed-dose combination tablets, genotyping could guide efavirenz dose reduction but would require more pills.
Methods: We assessed willingness to dose reduce among 129 patients at an HIV primary care clinic in the southeastern USA.
Results: When told that switching from one pill to two or three pills "might make you feel a little better", 47% expressed definite or possible willingness. This decreased to 9% if there was "a small chance it might not control your HIV as well". Clinical variables were not associated with willingness.
Conclusion: Many patients receiving a fixed-dose combination tablet may be willing to take more pills in order to dose reduce, guided by genetic testing, but only if virologic control is not compromised.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926164 | PMC |
| http://dx.doi.org/10.2217/pme-2015-0011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacokinetics of ethambutol and weight banded dosing in South African adults newly diagnosed with tuberculosis and HIV.
Antimicrob Agents Chemother
December 2024
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Ethambutol is used to treat tuberculosis (TB) in individuals living with HIV. Low concentrations of ethambutol have been reported in patients dosed with the World Health Organization (WHO)-recommended first-line regimen. We analyzed the pharmacokinetics of ethambutol in 61 HIV-positive individuals diagnosed with drug-sensitive TB enrolled in the tuberculosis and highly active antiretroviral therapy (TB-HAART) study.
View Article and Find Full Text PDFDetermining Targets for Antiretroviral Drug Concentrations: A Causal Framework Illustrated With Pediatric Efavirenz Data From the CHAPAS-3 Trial.
Pharmacoepidemiol Drug Saf
December 2024
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Background: Determining a therapeutic window for maintaining antiretroviral drug concentrations within an appropriate range is required for identifying effective dosing regimens. The limits of this window are typically calculated using predictive models. We propose that target concentrations should instead be calculated based on counterfactual probabilities of relevant outcomes and describe a counterfactual framework for this.
View Article and Find Full Text PDFChallenges and Opportunities for Consideration of Efavirenz Drug Repurposing for Alzheimer's Disease Therapeutics.
ACS Pharmacol Transl Sci
October 2024
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States.
Article Synopsis
- Therapeutic research on Alzheimer's disease (AD) has shifted towards drug repositioning, specifically looking at FDA-approved medications like efavirenz as potential AD treatments.
- At low doses, efavirenz activates the enzyme CYP46A1 which helps reduce excess brain cholesterol and improve memory deficits in AD models, showing promising effects without the neurotoxic risks associated with higher doses used for HIV treatment.
- The review highlights the need for further studies on efavirenz's properties, safety, and effectiveness to evaluate its potential as a candidate for AD drug development.
Causal Inference for Continuous Multiple Time Point Interventions.
Stat Med
December 2024
Division of Biostatistics, Department of Population Health, New York University Grossman School of Medicine, New York, New York, USA.
There are limited options to estimate the treatment effects of variables which are continuous and measured at multiple time points, particularly if the true dose-response curve should be estimated as closely as possible. However, these situations may be of relevance: in pharmacology, one may be interested in how outcomes of people living with-and treated for-HIV, such as viral failure, would vary for time-varying interventions such as different drug concentration trajectories. A challenge for doing causal inference with continuous interventions is that the positivity assumption is typically violated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!